INGELHEIM, Germany and INDIANAPOLIS, US--(BUSINESS WIRE)--For Non-U.S. and Non-U.K. Media
Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in adults with Type 2 Diabetes (T2D) at the American Diabetes Association’s 74th Scientific Sessions®. Results showed that empagliflozin in combination with certain other diabetes therapies reduced blood glucose, body weight and blood pressure.
Help employers find you! Check out all the jobs and post your resume.
